| 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 819,2 k € | -48.5% | 1,6 M € | -81.2% | 8,5 M € | +75.1% | 4,8 M € | +69.7% | 2,9 M € | -0.1% | 2,9 M € | -2.0% | 2,9 M € | +12.3% | 2,6 M € | -5.8% | 2,8 M € | +0.9% | 2,7 M € | -8.4% | 3,0 M € | -3.5% | 3,1 M € | +5.5% | 2,9 M € | +11.2% | 2,6 M € | +5253.5% | -51,0 k € | -137.9% | -21,5 k € | -42.6% | -15,0 k € | -328.9% | -3,5 k € | |
| EBITDA | 179,0 k € | -82.6% | 1,0 M € | -87.0% | 7,9 M € | +103.5% | 3,9 M € | +63.0% | 2,4 M € | -2.0% | 2,4 M € | -4.0% | 2,5 M € | +14.1% | 2,2 M € | -8.2% | 2,4 M € | +0.9% | 2,4 M € | -10.8% | 2,7 M € | -5.2% | 2,8 M € | +5.8% | 2,7 M € | +8.2% | 2,5 M € | +4303.7% | -58,9 k € | -166.2% | -22,1 k € | -41.9% | -15,6 k € | -268.9% | -4,2 k € | |
| Operating profit | 156,9 k € | -83.9% | 975,2 k € | -84.6% | 6,3 M € | +725.4% | 767,1 k € | +120.6% | 347,8 k € | -8.9% | 381,6 k € | -19.9% | 476,1 k € | +66.6% | 285,7 k € | -58.8% | 693,0 k € | +12.6% | 615,6 k € | -33.0% | 918,2 k € | -17.5% | 1,1 M € | +6.3% | 1,0 M € | +18.3% | 884,3 k € | +1602.0% | -58,9 k € | +46.2% | -109,5 k € | -602.2% | -15,6 k € | -268.9% | -4,2 k € | |
| Profit/loss | 418,4 k € | -53.8% | 905,3 k € | -81.8% | 5,0 M € | +930.6% | 483,4 k € | +177.0% | 174,5 k € | +17.3% | 148,7 k € | -21.9% | 190,5 k € | +473.8% | -51,0 k € | -119.0% | 268,3 k € | +21.7% | 220,5 k € | -44.8% | 399,7 k € | -18.6% | 491,2 k € | +10.6% | 444,1 k € | +42.4% | 311,9 k € | +256.2% | -199,6 k € | -89.1% | -105,6 k € | -947.8% | -10,1 k € | -305.0% | 4,9 k € | |
| Equity | 6,1 M € | +7.4% | 5,6 M € | +19.1% | 4,7 M € | +173.0% | 1,7 M € | -36.1% | 2,7 M € | +0.3% | 2,7 M € | -0.7% | 2,7 M € | -10.2% | 3,0 M € | -6.7% | 3,2 M € | -4.5% | 3,4 M € | -6.2% | 3,6 M € | +4.0% | 3,5 M € | +16.9% | 3,0 M € | +8.9% | 2,7 M € | +27.2% | 2,2 M € | +328.7% | 502,6 k € | +68.5% | 298,3 k € | -3.3% | 308,4 k € | |
| Total assets | 7,8 M € | -14.9% | 9,2 M € | -7.3% | 10,0 M € | +33.5% | 7,5 M € | -48.6% | 14,5 M € | -7.7% | 15,7 M € | -1.1% | 15,9 M € | -2.3% | 16,2 M € | -0.0% | 16,3 M € | -9.0% | 17,9 M € | -6.4% | 19,1 M € | -6.3% | 20,4 M € | -0.6% | 20,5 M € | -4.1% | 21,4 M € | -8.0% | 23,2 M € | +29.9% | 17,9 M € | +4060.0% | 429,5 k € | +38.6% | 309,9 k € | |
| Cash | 157,9 k € | -88.8% | 1,4 M € | -24.8% | 1,9 M € | -2.5% | 1,9 M € | -12.3% | 2,2 M € | +18.1% | 1,9 M € | -6.4% | 2,0 M € | +0.7% | 2,0 M € | -1.9% | 2,0 M € | -5.8% | 2,1 M € | +18.6% | 1,8 M € | -2.8% | 1,9 M € | +37.3% | 1,3 M € | +359.6% | 293,5 k € | -50.5% | 592,7 k € | +63.8% | 361,9 k € | +55.1% | 233,4 k € | -15.1% | 275,0 k € | |
| Debts | 348,5 k € | -69.9% | 1,2 M € | -59.2% | 2,8 M € | -47.4% | 5,4 M € | -50.2% | 10,9 M € | -10.1% | 12,1 M € | -7.4% | 13,1 M € | -0.3% | 13,1 M € | +1.8% | 12,9 M € | -10.1% | 14,3 M € | -6.4% | 15,3 M € | -8.3% | 16,7 M € | -3.4% | 17,3 M € | -5.9% | 18,3 M € | -8.5% | 20,1 M € | +15.5% | 17,4 M € | +13136.1% | 131,2 k € | +8330.6% | 1,6 k € | |
| Staff | 5,4 | 8 | 8 | 8 | 7,3 | 6,5 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 3,7 | 1 | — | — | — | ||||||||||||||||||
Public limited company · Tongeren-Borgloon · incorporated on 25/08/2004 · 5,4 ETP
Public limited company profitable and well capitalised. Cash position declining (-88.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
FRI-PHARMA is a Public limited company incorporated in 2004. Its main activity is: Warehousing and storage. Its registered office is in Tongeren-Borgloon. It employs on average 5,4 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette